• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

byNeil D'SouzaandShaidah Deghan, MSc. MD
April 8, 2016
in Neurology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In grade 2 glioma patients younger than 40 years old that have undergone subtotal tumour resection, or in patients 40 years of age and older, the combination of chemotherapy and radiation confers a longer progression-free and overall survival compared to radiation therapy alone.

2. The frequency and severity of toxicity was greater in the radiation plus chemotherapy arm, with most side effects being of grade 1 or 2 in nature. There were no grade 5 toxic effects, or instances of myelodysplasia or leukemia.

Evidence Rating Level: 1 (Excellent)

Study Rundown:  Grade 2 gliomas are relatively uncommon primary adult brain tumours, causing inevitable neurologic sequelae and premature death. A prior phase II study using the chemotherapy regimen of procarbazine, lomustine (also called CCNU) and vincristine showed a tumour regression benefit post radiation therapy, after a median follow-up time of 5.9 years. This study was a phase III trial using the same chemotherapy regimen above, but randomized to include radiation therapy or radiation therapy alone, in addition to long-term follow-up. In the radiation therapy and chemotherapy arm, progression-free survival and overall survival were longer compared to radiation therapy alone.  This effect was greatest in patients with oligodendroglioma or oligoastrocytoma, and with patients having IDH1 R132H mutations. There were more instances of grade 1 and 2 toxicity in the combination therapy group (e.g. fatigue, nausea, vomiting, anorexia).  There were no reports of any grade 5 toxicities in either of the treatment arms.  Strengths of this study include randomized controlled trial methodology, and long-term follow-up not previously achieved in other studies.  Limitations include the small patient numbers and single institution data. Favourable prognosticators for progression-free and overall survival included receiving radiation plus chemotherapy, and oligodendroglioma histology.

Click to read the study, published today in NEJM

Relevant Reading: Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802

RELATED REPORTS

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas

In-Depth [randomized controlled trial]: This phase III trial provided long-term survival data from grade 2 glioma patients receiving procarbazine, CCNU and vincristine, plus radiation therapy, versus radiation therapy alone. Patients included those having grade 2 astrocytoma, oligoastrocytoma or oligodendroglioma, who were younger than 40 years old and had subtotal resection or biopsy, or who were 40 years of age or older.  These patients were randomly assigned to radiation therapy alone, or radiation therapy followed by 6 cycles of chemotherapy.

There were a total of 254 patients who underwent randomization between 1998 to 2002: 128 patients in the radiation therapy alone group, and 126 patients in the radiation therapy plus chemotherapy group. The median follow-up time was 11.9 years and at the time of analysis, 67% of enrolled patients had tumour progression, and 55% died.  Patients receiving radiation therapy and chemotherapy had a longer progression-free survival (10.4 years; 95% [CI], 6.1 to not reached) compared to those receiving radiotherapy alone (4.0 years, 95% [CI], 3.1 to 5.5).  The overall survival for radiation plus chemotherapy was significantly longer compared to radiation therapy alone (13.3 vs. 7.8 years; HR for death, 0.59; p=0.03).

Image: CC/Kalinin

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: glioma
Previous Post

Statins reduce the risk of cardiovascular disease in intermediate risk patients: The HOPE-3 trial

Next Post

Infertility linked to higher birth defect risk

RelatedReports

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
StudyGraphics

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

August 25, 2023
Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]
Oncology

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

August 21, 2023
Combined MRI and NIH stroke scores may predict stroke prognosis
Neurology

Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas

December 1, 2021
Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas
Neurology

Immunovirotherapy showed acceptable adverse-event profile in pediatric high-grade gliomas

April 20, 2021
Next Post
Infertility treatments not associated with increased short-term cancer risk

Infertility linked to higher birth defect risk

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Paroxetine a good non-hormonal option for hot flashes

Fruit consumption among US youth differs by age, race

Eating fresh fruit decreased the risk of cardiovascular disease in Chinese adults: The China Kadoorie Biobank Study

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.